Labcorp Holdings (LH) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
13.0B
Gross Profit
3.6B
27.86%
Operating Income
1.1B
8.75%
Net Income
747.1M
5.74%
EPS (Diluted)
$8.84
Balance Sheet Metrics
Total Assets
18.4B
Total Liabilities
10.3B
Shareholders Equity
8.1B
Debt to Equity
1.28
Cash Flow Metrics
Operating Cash Flow
1.7B
Free Cash Flow
1.1B
Revenue & Profitability Trend
Labcorp Holdings Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 13.0B | 12.2B | 11.9B | 13.1B | 14.0B |
| Cost of Goods Sold | 9.4B | 8.8B | 8.2B | 8.1B | 9.0B |
| Gross Profit | 3.6B | 3.4B | 3.7B | 5.0B | 5.0B |
| Operating Expenses | 2.2B | 2.0B | 1.8B | 1.7B | 1.7B |
| Operating Income | 1.1B | 1.1B | 1.8B | 3.1B | 2.9B |
| Pre-tax Income | 959.5M | 568.9M | 1.2B | 2.9B | 2.2B |
| Income Tax | 212.4M | 188.5M | 233.9M | 690.0M | 662.1M |
| Net Income | 747.1M | 419.2M | 1.3B | 2.4B | 1.6B |
| EPS (Diluted) | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 |
Income Statement Trend
Labcorp Holdings Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 4.8B | 3.8B | 4.6B | 5.3B | 5.1B |
| Non-Current Assets | 13.6B | 13.0B | 15.5B | 15.1B | 14.9B |
| Total Assets | 18.4B | 16.7B | 20.2B | 20.4B | 20.1B |
| Liabilities | |||||
| Current Liabilities | 3.3B | 3.2B | 3.1B | 2.8B | 3.1B |
| Non-Current Liabilities | 7.0B | 5.6B | 7.0B | 7.3B | 7.5B |
| Total Liabilities | 10.3B | 8.8B | 10.0B | 10.1B | 10.6B |
| Equity | |||||
| Total Shareholders Equity | 8.1B | 7.9B | 10.1B | 10.3B | 9.5B |
Balance Sheet Composition
Labcorp Holdings Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 747.1M | 380.4M | 1.0B | 2.2B | 1.6B |
| Operating Cash Flow | 1.7B | 1.2B | 2.2B | 3.2B | 1.4B |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Investing Cash Flow | -876.9M | -693.2M | -1.2B | -424.2M | -261.5M |
| Financing Activities | |||||
| Dividends Paid | -243.1M | -254.0M | -195.2M | 0 | 0 |
| Financing Cash Flow | 723.7M | -1.6B | -534.8M | -2.1B | -517.4M |
| Free Cash Flow | 1.1B | 874.1M | 1.5B | 2.7B | 1.8B |
Cash Flow Trend
Labcorp Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
29.68
Forward P/E
16.17
Price to Book
2.61
Price to Sales
1.65
PEG Ratio
16.17
Profitability Ratios
Profit Margin
5.55%
Operating Margin
9.94%
Return on Equity
8.98%
Return on Assets
4.18%
Financial Health
Current Ratio
1.84
Debt to Equity
79.13
Beta
0.79
Per Share Data
EPS (TTM)
$8.73
Book Value per Share
$99.13
Revenue per Share
$157.30
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| lh | 21.7B | 29.68 | 2.61 | 8.98% | 5.55% | 79.13 |
| Thermo Fisher | 160.9B | 25.00 | 3.26 | 13.70% | 15.19% | 69.23 |
| Danaher | 144.7B | 39.25 | 2.84 | 7.22% | 15.81% | 34.56 |
| Idexx Laboratories | 43.5B | 49.74 | 30.15 | 59.33% | 22.76% | 73.16 |
| Agilent Technologies | 34.4B | 29.88 | 5.60 | 18.88% | 17.59% | 60.04 |
| Iqvia Holdings | 28.5B | 22.41 | 4.79 | 21.64% | 8.61% | 242.91 |
Financial data is updated regularly. All figures are in the company's reporting currency.